Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The University of Oxford and Oxford University Hospitals NHS Foundation Trust (OUH) have won £113.7 million to support groundbreaking medical research.

The Nuffield Department of Orthopaedics, Rheumatology & Musculoskeletal Sciences (NDORMS) is leading two of the themes of the new NIHR Oxford Biomedical Research Centre (BRC), in Musculoskeletal sciences (Professor Andrew Carr) and Gastroenterology & Mucosal Immunity (Professor Fiona Powrie).

The National Institute for Health Research (NIHR), which is funded through the Department for Health, today announced that the Oxford BRC was one of 20 successful BRCs throughout England to receive funding for 2017 to 2022 following a competitive bidding process. NIHR BRCs bring together expertise within the NHS and leading research organisations to turn latest discoveries into fundamentally new treatments for patients.

The musculoskeletal theme now in the NIHR Oxford BRC replaces the current NIHR Oxford Musculoskeletal Biomedical Research Unit (BRU), to end in March 2017.

Professor Andrew Carr, Head of Department and theme lead on the new NIHR Oxford BRC, said: 'We are delighted to lead two themes in this successful NIHR Oxford BRC, building on the excellence of translational research of our NIHR Oxford BRU. The close working relationship between basic scientists and clinicians fostered by the BRC partnerships has already led to novel treatments and will continue to allow us to improve the lives of our patients.'

MUSCULOSKELETAL THEME

Our vision is to build on our established and proven strengths in the identification of therapeutic targets and to accelerate the translation of new personalized therapies in inflammatory joint disease, degenerative joint disorders and in rare bone diseases. We will also further develop and translate Oxford's promising tissue engineering implants and devices and regenerative medicine therapies for the benefit of patients.

GASTROENTEROLOGY & MUCOSAL IMMUNITY THEME

Inflammation underpins many common gastrointestinal tract and liver (GI) and skin diseases, such as inflammatory bowel disease (IBD), primary sclerosing cholangitis (PSC), non-alcoholic fatty liver disease (NAFLD), psoriasis and atopic dermatitis (AD) that are a significant source of morbidity and mortality. We will examine molecular pathogenesis in well characterised patient cohorts to identify unique and common drivers of chronic inflammatory GI and skin diseases. This will enable enhanced diagnosis and treatment strategies ensuring expensive immunotherapies with potential side effects are targeted to those patients most likely to benefit.


Similar stories

Novo Nordisk Postdoctoral Research Fellowship awarded to Inhye Park

Inhye Park has been awarded a Novo Nordisk Postdoctoral Research Fellowship to research the biology of resident vascular macrophages in atherosclerosis.

The Kennedy Institute Student Symposium returns for its 5th year

A two-day student symposium returned to the Kennedy Institute bringing together students and peers from across the department to discuss their latest research.

Researchers from the Kennedy Institute awarded MRC funding

Tonia Vincent, Jelena Bezbradica and Alex Clarke have been awarded funding grants by the Medical Research Council (MRC) for different projects.

The Kennedy Institute completes its roof extension

Building work at the Kennedy Institute of Rheumatology has finished, providing a new third floor that houses additional meeting and collaboration space for data science and offices for the management of clinical trials.

EPSRC funds research to avert an antibiotics apocalypse

Researchers at the Kennedy Institute join a collaboration to find new ‘drug-free’ ways of treating illnesses where current treatments have become ineffective due to antibiotic resistance.

Major ERC funding awarded to Professor Michael Dustin

Professor Michael Dustin and an international team of collaborators have been awarded a €10M grant from the European Research Council (ERC) to develop a new biotechnology around supramolecular attack particles (SMAPs) engineered to kill cancer cells.